Genetic risk assessment and prevention: the role of genetic testing panels in breast cancer

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Expert Review of Anticancer Therapy

• Publication date

  2015-11-02

• Fields of study

  Medicine

• Identifiers
  DOI 10.1586/14737140.2015.1090879PMID 26523341
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Genetic testing for RAD51C mutations: in the clinic and community

  2015cited by this paper
• Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next‐generation sequencing with a 25‐gene panel

  2015cited by this paper
• HBOC multi-gene panel testing: comparison of two sequencing centers

  2015cited by this paper
• Germline RECQL mutations are associated with breast cancer susceptibility

  2015cited by this paper
• Testing for Hereditary Breast Cancer: Panel or Targeted Testing? Experience from a Clinical Cancer Genetics Practice

  2015cited by this paper
• Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer.

  2015influential reference
• Clinical outcomes in women with breast cancer and a PALB2 mutation: a prospective cohort analysis.

  2015cited by this paper
• Beyond BRCA: new hereditary breast cancer susceptibility genes.

  2015cited by this paper
• Identification of a Comprehensive Spectrum of Genetic Factors for Hereditary Breast Cancer in a Chinese Population by Next-Generation Sequencing

  2015cited by this paper
• Gene-panel sequencing and the prediction of breast-cancer risk.

  2015cited by this paper
• Mutations predisposing to breast cancer in 12 candidate genes in breast cancer patients from Poland

  2015cited by this paper
• Utilization of multigene panels in hereditary cancer predisposition testing: analysis of more than 2,000 patients

  2014cited by this paper
• Genetic/familial high-risk assessment: breast and ovarian, version 1.2014.

  2014cited by this paper
• Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment.

  2014cited by this paper
• Breast-cancer risk in families with mutations in PALB2.

  2014cited by this paper
• Inherited predisposition to breast cancer among African American women

  2014cited by this paper
• The Validation and Clinical Implementation of BRCAplus: A Comprehensive High-Risk Breast Cancer Diagnostic Assay

  2014cited by this paper
• Rare key functional domain missense substitutions in MRE11A, RAD50, and NBN contribute to breast cancer susceptibility: results from a Breast Cancer Family Registry case-control mutation-screening study

  2014cited by this paper
• Prevalence of mutations in a panel of breast cancer susceptibility genes in BRCA1/2 negative patients with early onset breast cancer

  2014cited by this paper
• Next-generation sequencing for the diagnosis of hereditary breast and ovarian cancer using genomic capture targeting multiple candidate genes

  2014cited by this paper
• Breast-cancer risk in families with mutations in PALB2.

  2014cited by this paper
• The impact of next generation sequencing on the analysis of breast cancer susceptibility: a role for extremely rare genetic variation?

  2013cited by this paper
• The integration of next-generation sequencing panels in the clinical cancer genetics practice: an institutional experience

  2013cited by this paper
• Lifetime Cancer Risks in Individuals with Germline PTEN Mutations

  2012cited by this paper
• Germline RAD51C mutations confer susceptibility to ovarian cancer

  2012cited by this paper
• Germline RAD51C mutations confer susceptibility to ovarian cancer

  2012cited by this paper
• Current evidence on the relationship between two polymorphisms in the NBS1 gene and breast cancer risk: a meta-analysis.

  2012cited by this paper
• Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals

  2011cited by this paper
• Rare variants in the ATM gene and risk of breast cancer

  2011cited by this paper
• Risk of breast cancer in women with a CHEK2 mutation with and without a family history of breast cancer.

  2011cited by this paper
• Genetic susceptibility to breast cancer

  2010cited by this paper
• Rare, evolutionarily unlikely missense substitutions in ATM confer increased risk of breast cancer.

  2009cited by this paper
• Penetrance estimates for BRCA1 and BRCA2 based on genetic testing in a Clinical Cancer Genetics service setting: Risks of breast/ovarian cancer quoted should reflect the cancer burden in the family

  2008cited by this paper
• Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer.

  2006cited by this paper
• ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles

  2006cited by this paper
• Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles

  2006cited by this paper
• Population‐based estimates of breast cancer risks associated with ATM gene variants c.7271T>G and c.1066–6T>G (IVS10–6T>G) from the Breast Cancer Family Registry

  2006cited by this paper
• Frequency and Spectrum of Cancers in the Peutz-Jeghers Syndrome

  2006cited by this paper
• Genetic Susceptibility to Prostate, Breast, and Colorectal Cancer among Nordic Twins

  2005cited by this paper
• RAD50 and NBS1 are breast cancer susceptibility genes associated with genomic instability.

  2005cited by this paper
• Mutation screening of Mre11 complex genes: indication of RAD50 involvement in breast and ovarian cancer susceptibility

  2003cited by this paper
• Germline p53 mutations in a cohort with childhood sarcoma: sex differences in cancer risk.

  2003cited by this paper
• Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families.

  2001cited by this paper
• The National Comprehensive Cancer Network

  1998cited by this paper
• Identification of the breast cancer susceptibility gene BRCA2

  1996cited by this paper
• Identification of the breast cancer susceptibility gene BRCA2

  1995cited by this paper
• A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1.

  1994cited by this paper
• Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families.

  1994cited by this paper

• Economic evaluation of germline genetic testing for breast cancer in low- and middle-income countries: a systematic review

  2024cites this paper
• Investigating the effects of the ARG258HIS mutation on RAD51C in inherited Fanconi Anemia and cancer disease

  2024cites this paper
• Multigenic panels in breast cancer: clinical utility and management of patients with pathogenic variants other than BRCA1/2.

  2024cites this paper
• Genetic counseling and genetic testing for pathogenic germline mutations among high-risk patients previously diagnosed with breast cancer: a traceback approach

  2024cites this paper
• Implementation of BRCA mutations testing in formalin-fixed paraffin-embedded (FFPE) samples of different cancer types.

  2023cites this paper
• Recontact to return new or updated PALB2 genetic results in the clinical laboratory setting

  2023cites this paper
• Delineating intra-tumoral heterogeneity and tumor evolution in breast cancer using precision-based approaches

  2023influential citation
• Principles of molecular testing for hereditary cancer

  2022influential citation
• Bioinformatic investigation and functional analysis of 214 hereditary genes identified non-coding RNAs as therapeautic tool for breast cancer management

  2022cites this paper
• Preventive population genomics: The model of BRCA related cancers.

  2021cites this paper
• Discrepancies in Genetic Testing Procedures of BRCA1/2 Mutations: A National Survey Across China

  2020cites this paper
• Identification and characterisation of germline variants in an Irish cohort with breast cancer

  2020cites this paper
• Multigene panel testing for hereditary breast and ovarian cancer in the province of Ontario

  2020influential citation
• Exon splicing analysis of intronic variants in multigene cancer panel testing for hereditary breast/ovarian cancer

  2020cites this paper
• Diagnostic yield of a custom-designed multi-gene cancer panel in Irish patients with breast cancer

  2020cites this paper
• Breast Cancer Prevention

  2019cites this paper
• Knowledge, attitudes, and perceived barriers towards genetic testing across three rural Illinois communities

  2019cites this paper
• Retesting of women who are negative for a BRCA1 and BRCA2 mutation using a 20-gene panel

  2019cites this paper
• A Cost-effectiveness Analysis of Multigene Testing for All Patients With Breast Cancer

  2019cites this paper
• Genomic and transcriptional heterogeneity-based precision in personalized treatment for breast cancer.

  2019cites this paper
• An update on genetic risk assessment and prevention: the role of genetic testing panels in breast cancer

  2019cites this paper
• Multi gene panel testing for hereditary breast cancer - is it ready to be used?

  2019cites this paper
• Trastuzumab and Docetaxel Combination Therapy Compared to Docetaxel Monotherapy in HER2-Positive Stage IV Metastatic Breast Cancer: An Open Labelled Randomized Study

  2019cites this paper
• Breast Cancer Susceptibility—Towards Individualised Risk Prediction

  2019cites this paper
• Next-generation sequencing-based clinical sequencing: toward precision medicine in solid tumors

  2018cites this paper
• Cost-effectiveness of Population-Based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 Mutation Testing in Unselected General Population Women

  2018cites this paper
• Mutation screening of 10 cancer susceptibility genes in unselected breast cancer patients

  2018cites this paper
• Regulatory variants in cancer-related pathway genes predict survival of patients with surgically resected non-small cell lung cancer.

  2018cites this paper
• Current review of TP53 pathogenic germline variants in breast cancer patients outside Li‐Fraumeni syndrome

  2018cites this paper
• Boosting care and knowledge about hereditary cancer: European Reference Network on Genetic Tumour Risk Syndromes

  2018cites this paper
• Next generation sequencing‐based gene panel tests for the management of solid tumors

  2018cites this paper
• Personalised medicine and population health: breast and ovarian cancer

  2018cites this paper
• Bilateral Breast Cancer

  2018cites this paper
• Hereditary breast cancer in South-Eastern Norway BRCA1/2- testing of breast cancer patients. Mutation spectrum and potential modifiers in Norwegian BRCA1/2 carriers

  2018cites this paper
• Next-Generation Sequencing in Oncology: Genetic Diagnosis, Risk Prediction and Cancer Classification

  2017cites this paper
• A Comparison of Whole Genome Sequencing to Multigene Panel Testing in Hypertrophic Cardiomyopathy Patients

  2017cites this paper
• Breast cancer risk and clinical implications for germline PTEN mutation carriers

  2017cites this paper
• Next Generation Sequencing and Multi-Gene Panel Testing: Implications for the Oncology Nurse.

  2017cites this paper
• Multigene testing for breast cancer risk assessment: an illusion of added clinical value.

  2017influential citation
• PALB2 mutations in BRCA1/2-mutation negative breast and ovarian cancer patients from Poland

  2017cites this paper
• 3 Cirino at al Comparing Panel and Whole Genome Sequencing in HCM Results Patient Characteristics

  2017cites this paper
• Current guidelines for BRCA testing of breast cancer patients are insufficient to detect all mutation carriers

  2017cites this paper
• Non-BRCA1/2 Breast Cancer Susceptibility Genes: A New Frontier with Clinical Consequences for Plastic Surgeons

  2017cites this paper
• Coming of age in Canada: a study of population-based genetic testing for breast and ovarian cancer.

  2017cites this paper
• A Multigene Test Could Cost-Effectively Help Extend Life Expectancy for Women at Risk of Hereditary Breast Cancer.

  2017cites this paper
• The role of screening MRI in the era of next generation sequencing and moderate-risk genetic mutations

  2017cites this paper
• Next-Generation Sequencing Based Testing for Breast Cancer

  2016cites this paper
• Síndrome de cáncer de mama y ovario hereditario: Estudio in vitro de variantes BRCA1 y BRCA2 de significado biológico desconocido y búsqueda de nuevos genes responsables de este síndrome

  2016cites this paper
• Rare variants in BRCA2 and CHEK2 are associated with the risk of urinary tract cancers

  2016cites this paper
• Environmental Chemical Assessment in Clinical Practice: Unveiling the Elephant in the Room

  2016cites this paper
• Identification and Management of Hereditary Cancer Syndromes: A Public Health Priority

  2014cites this paper
• Breast Cancer Prevention

  2014cites this paper